T Rachocki

Suggest Changes
  • Citations Per Year
Learn More
e16025 Background: Favorable response at the primary tumor site to IC (with cisplatin and 5-FU) correlates with disease control after subsequent definitive radiation-based therapy (RT) in pts with(More)
5560 Background: Achievement of a complete (CR) or partial (PR) response at the PTS to IC with cisplatin and 5-FU correlates with disease control after subsequent definitive radiation-based therapy(More)
5569 Background: The likelihood of tumor response (CR/PR) to cetuximab is 13% as assessed by CT with IV contrast in patients with incurable HNSCC; however, stable disease occurred in an additional(More)
  • 1